p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis

International Journal of Cancer

Volumn 123, Issue 5, 2008, Pages 1060-1067

  Díaz, Raquel ^a   Peña, Cristina ^a   Silva, Javier ^a   Lorenzo, Yolanda ^a   García, Vanesa ^a   García, José M ^a   Sánchez, Antonio ^a   Espinosa, Pablo ^a   Yuste, Rosario ^a   Bonilla, Félix ^a   Domínguez, Gemma ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Angiogenesis; p73 isoforms; VEGF; VEGF165b and PEDF

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; ISOPROTEIN; K RAS PROTEIN; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN P53; PROTEIN P73; TRANSCRIPTION FACTOR E2F1; VASCULOTROPIN; VASCULOTROPIN 165; DNA BINDING PROTEIN; EYE PROTEIN; MESSENGER RNA; NERVE GROWTH FACTOR; NUCLEAR PROTEIN; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ANGIOGENESIS; ARTICLE; CANCER PATIENT; CANCER TISSUE; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DOWN REGULATION; EXON; FEMALE; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; COLORECTAL TUMOR; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; NEOVASCULARIZATION (PATHOLOGY); ONCOGENE RAS; PATHOLOGY; PREDICTION AND FORECASTING;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; EYE PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERPINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47249094555     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23619     Document Type: Article

References (45)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic swith during tumorigenesis. Cell 1996;86:353-64.
2. Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc Med 1993;3:244-50.
3. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333-40.
4. Liu Y, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 1995;77:638-43.
5. 2 tension. Am J Physiol 1996;271:1172-80.
6. Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O, Chung DC. Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 2004;65:1765-72.
7. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995;55:6161-5.
8. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metast Rev 1995;14:263-77.
9. Zhu Y, Jin K, Mao XO, Greenberg DA. Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression. FASEB J 2003;17:186-93.
10. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
11. Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 1999;81:845-50.
12. Gasparini G. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 2001;37:97-114.
13. Paradis V, Lagha NB, Zeimoura L, Blanchet P, Eschwege P, Ba N, Benoit G, Jardin A, Bedossa P. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 2000;436:351-6.
14. Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996;78:226-31.
15. Vermeulen PB, Van den Eynden GG, Huget P, Goovaerts G, Weyler J, Lardon F, Van Marck E, Hubens G, Dirix LY. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999;79:316-22.
16. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamoki N, Nakamura M. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998;77:998-1002.
17. Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PWT, Charnsangavej C, Delclos ME, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006;24:1145-51.
18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
19. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806-14.
20. 183, a novel spliced variant of vascular growth factor. Investig Ophthalmol Vis Sci 1999;40:752-9.
21. 145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997;272:7151-8.
22. 148 mRNA, a novel truncated splice variant. Clin Sci (Colch) 1999;97:303-12.
23. 165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004;64:7822-35.
24. 165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 2002;62:4123-31.
25. Pritchard-Jones RO, Dunn DB, Oju Y, Varey AH, Orlando A, Rigby H, Harper SJ, Bates DO. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer 2007;97:223-30.
26. Salimath B, Marme D, Finkenzeller G. Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene 2000;19:3470-6.
27. Vikhanskaya F, Bani MR, Borsotti P, Ghilardi C, Ceruti R, Ghisleni G, Marabese M, Giavazzi R, Broggini M, Taraboletti G. p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene 2001;20:7293-300.
28. Guan M, Peng HX, Yu B, Lu Y. p73 overexpression and angiogenesis in human colorectal carcinoma. Jpn J Clin Oncol 2003;33:215-20.
29. Jost CA, Marin MC, Kaelin WG, Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997;389:191-4.
30. Domínguez G, García JM, Peña C, Silva J, García V, Martínez L, Maximiano C, Gómez ME, Rivera JA, García-Andrade C, Bonilla F. ΔTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53 and, E2F-1. J Clin Oncol 2006;24:805-15.
31. Senoo M, Matsumura Y, Habu S. TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascualr endotelial growth factor (VEGF) gene expression. Oncogene 2002;21:2455-65.
32. Sasaki Y, Naishiro Y, Oshima Y, Imai K, Nakamura Y, Tokino T. Identification of pigment epithelim-derived factor as a direct target of the p53 family member genes. Oncogene 2005;25:5131-6.
33. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu HJ, Benedict W, Bouck NP. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8.
34. Crawford SE, Stellmach V, Ranalli M, Huang X, Huang L, Volpert O, De Vries GH, Abramson LP, Bouck N. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001;114:4421-8.
35. Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J, Crawford SE. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003;9:774-80.
36. Matsumoto K, Ishikawa H, Nishimura D, Hamasaki K, Nakao K, Eguchi K. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology 2004;40:252-9.
37. Garcia M, Fernandez-Garcia NI, Rivas V, Carretero M, Escamez MJ, Gonzalez-Martin A, Medrano EE, Volpert O, Jorcano JL, Jimenez B, Larcher F, Del Rio M. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. CancerRes 2004;64:5632-42.
38. Guan M, Yam H-F, Su B, Chan K-P, Pang C-P, Liu W-W, Zhang W-Z, Lu Y. Loss of pigment epithelium derived factor expression in glioma progression. J Clin Pathol 2003;56:277-82.
39. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H, Hashimoto H, Murakami Y, Hase R, Takahashi R, Mega S, Shichinohe T, Kawarada Y, et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004;64:3533-7.
40. Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J. Contrasting effect of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J 2003;22:4091-102.
41. Takenaka K, Yamagishi SI, Jinnouchi Y, Nakamura K, Matsui T, Imaizumi T. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci 2005;77:3232-41.
42. Miyagishi D, Ohno-Matsui K, Amagasa T, Morita I. Regulation of the expression of pigment epithelium-derived factor, an anti-angiogenic factor in human oral squamous cell carcinoma cell lines. Cancer Lett 2003;196:77-85.
43. Oto M, Miyake S, Yuasa Y. Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus. Ann Biochem 1993;213:19-22.
44. Domínguez G, Silva J, Silva JM, Garcia JM, Larrondo FJ, Vargas J, Sanfrutos L, Provencio M, España P, Bonilla F. Different expression of P14ARF defines two groups of breast carcinomas in terms of TP73 expression and TP53 mutational status. Genes Chromosomes Cancer 2001;31:99-106.
45. Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996;88:173-82.